0.9000USD-23.08%Mkt Cap: 4.36M USDP/E: —Last update: 2026-06-01
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials …
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap4.36M USD
Enterprise Value4.32M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-39.22M USD
Revenue/Share—
Last Price0.9000 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.17
EV/Revenue—
P/S—
P/B-0.01
EPS (TTM)-1177.89
EPS (Forward)—
52W Range
0.79320% of range848.00
52W High848.00 USD
52W Low0.7932 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE547.06%
ROA-694.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.55M USD
CapEx (TTM)2.40M USD
FCF Margin—
FCF Yield119.73%
Net Debt-734.00K USD
Net Debt/EBITDA0.03
Balance Sheet
Debt/Equity-0.11
Current Ratio0.34
Quick Ratio0.12
Book Value/Sh-77.8160 USD
Cash/Share0.3110 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateMar 27, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.86M
Float2.29M
Insiders77.87%
Institutions0.00%
Short Interest
Short Ratio0.4d
Short % Float1.23%
Short % Out.0.65%
Shares Short31.35K
Short (prev mo.)20.71K
Technical
SMA 504.291 (-79.0%)
SMA 20068.00 (-98.7%)
Beta1.57
S&P 52W Chg27.94%
Avg Vol (30d)1.63M
Avg Vol (10d)434.14K
Technical Indicators
RSI (14)29.4
MACD-0.9730
MACD Signal-1.1673
MACD Hist.+0.1944
BB Upper2.591 USD
BB Middle1.622 USD
BB Lower0.6530 USD
BB Width119.49%
ATR (14)0.5035 USD
Vol Ratio (20d)190.85x